Talazoparib versus chemotherapy in patients with germline BRCA1/2-mutated HER2-negative advanced breast cancer: final overall survival results from the EMBRACA trial - Concepedia

Concepedia

Publication | Open Access

Talazoparib versus chemotherapy in patients with germline BRCA1/2-mutated HER2-negative advanced breast cancer: final overall survival results from the EMBRACA trial

DOI Full Paper Access

372

Citations

15

References

2020

Year

Jennifer K. Litton, Sara A. Hurvitz, Lida A. Mina, Hope S. Rugo, Ki Hoon Lee, Anthony Gonçalvès, Sami Diab, Natasha Woodward, Annabel Goodwin, Rinat Yerushalmi,

Annals of Oncology

References

	Year	Citations

Page 1